Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Momelotinib gains full US approval in a broader setting than expected, validating GSK’s $1.9bn buyout of Sierra Oncology.
Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.
The big pharma group had two anti-BCMA assets to choose from, and yesterday gave Harpoon the bad news.
Lung cancer will soon join melanoma as a phase 3 indication for mRNA-4157, an asset Merck & Co last year endorsed to the tune of $250m.
A flurry of activity around USP1 inhibition suggests growing interest in this novel DNA damage response mechanism.
A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.